Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

dawn.com - Ikram Junaidi - Gulf crisis sparks drug supply fears; pharma costs seen rising
Gulf crisis sparks drug supply fears; pharma costs seen rising
Dawn

• Drap says Pakistan has sufficient drug stocks for three months, with alternative supply routes being explored • Pharmaceutical manufacturers foresee rising production costs due to higher energy prices and possible rupee devaluation…

freightwaves.com - Eric Kulisch - Lufthansa Cargo targets high-value tech, auto, pharma sectors
Lufthansa Cargo targets high-value tech, auto, pharma sectors
FreightWaves

Lufthansa Cargo last year devoted more strategic focus to serving the pharmaceutical, automotive, aviation, semiconductor and airmail sectors, creating additional avenues for profitable growth beyond general freight. The expansion of high-margin…

newswire.ca - Optel Group - OPTEL and Kaster Technologies partner to Bring AI-Driven Production Planning Intelligence to Pharma
OPTEL and Kaster Technologies partner to Bring AI-Driven Production Planning Intelligence to Pharma
CNW

QUEBEC CITY, March 17, 2026 /CNW/ - OPTEL, a global leader in traceability and compliance solutions, and Kaster Technologies, a specialist in AI-powered production planning intelligence software, have announced a strategic commercial partnership to…

newswire.ca - Corporation JAMP Pharma - JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide
JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide
CNW

A new generic option of Enzalutamide, an oncology medication used for the treatment of certain stages of prostate cancer. It is an orally administered antiandrogen. JAMP Pharma Group is launching JAMP Enzalutamide, a generic alternative to the…

newswire.ca - Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest
Innocan Pharma Announces Closing of a Debenture to its Largest Shareholder, Tamar Innovest
CNW

HERZLIYA, Israel and CALGARY, AB, March 16, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan') is pleased to announce that it has closed its previously announced offering of a debenture of the…

koreaherald.com - Lee Han-gyoul - Celltrion lands W295b CMO deal with global pharma
Celltrion lands W295b CMO deal with global pharma
The Korea Herald

Celltrion said Tuesday it has signed a 294.9 billion won ($198 million) contract manufacturing agreement with an undisclosed global pharmaceutical company to supply drug substance. The three-year deal runs from 2027 to 2029 and includes an option…

benzinga.com - Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP)
Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP)
Benzinga

Ketamine is a dissociative anesthetic that has some hallucinogenic effects. It is primarily used in medical and veterinary settings for surgery and pain management, and increasingly for mental health treatment. The FDA has confirmed its willingness…

thedailyrecord.com - Ian Round - Family of Henrietta Lacks reaches third Big Pharma settlement - Maryland Daily Record
Family of Henrietta Lacks reaches third Big Pharma settlement - Maryland Daily Record
Maryland Daily Record - Maryland Daily Record

This website uses cookies, web beacons, pixels, tags, software development kits, and related tracking technologies, as described in our Privacy Policy and Cookie Policy, for purposes that may include website operation, analytics, analyzing site…

marketbeat.com - 35,962 Shares in Ascendis Pharma A/S $ASND Acquired by Jain Global LLC
35,962 Shares in Ascendis Pharma A/S $ASND Acquired by Jain Global LLC
MarketBeat

Jain Global LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 35,962 shares of the biotechnology company's…

marketbeat.com - OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February
MarketBeat

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 435,430 shares, a drop of 12.4% from the February 12th total of…

marketbeat.com - OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2% - Time to Buy?
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2% - Time to Buy?
MarketBeat

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report)'s share price traded up 1.2% during mid-day trading on Monday. The company traded as high as $1.71 and last traded at $1.68. 29,325 shares changed hands during trading, a decline of…

marketbeat.com - OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of 'Hold' from Analysts
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of 'Hold' from Analysts
MarketBeat

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO - Get Free Report) have received a consensus rating of 'Hold' from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating…

marketbeat.com - Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC
Royalty Pharma PLC $RPRX Shares Bought by L2 Asset Management LLC
MarketBeat

L2 Asset Management LLC grew its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 1,264.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 92,215 shares of the…

marketbeat.com - Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock
MarketBeat

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the company's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $68.73, for a total value of $2,749,200.00.

marketbeat.com - Moore Capital Management LP Lowers Stock Position in Ascendis Pharma A/S $ASND
Moore Capital Management LP Lowers Stock Position in Ascendis Pharma A/S $ASND
MarketBeat

Moore Capital Management LP cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 25.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund…

Receive a Daily briefing on Pharma Industry News

Get Started